<DOC>
	<DOCNO>NCT00334802</DOCNO>
	<brief_summary>To investigate efficacy , safety PK gemcitabine paclitaxel combination patient metastatic breast cancer adjuvant/neo-adjuvant chemotherapy anthracycline regimen</brief_summary>
	<brief_title>Combination Chemotherapy Gemcitabine Paclitaxel Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Histologically and/or cytologically confirm breast cancer Received adjuvant/neoadjuvant chemotherapy breast cancer anthracycline regimen To least one measurable region Eastern Cooperative Oncology Group ( ECOG ) Performance Status : 01 To adequate organ function ( bone marrow , liver renal function ) To interstitial pneumonia pulmonary fibrosis To inflammatory breast cancer Within 28 day late chemotherapy radiotherapy , 14 day late hormonal/immunotherapy 7 day surgery To brain metastasis symptom To severe complication ( cardiac infarction , infection , drug hypersensitivity diabetes )</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>March 2010</verification_date>
</DOC>